Grifols announces US launch and distribution plans for Yimmugo

Spanish plasma-based medicines producer Grifols (MCE: GRF) announced the expected launch in the first quarter of 2025 for Yimmugo, an innovative immunoglobulin (Ig) therapeutic approved in the US for substitution therapy in primary antibody deficiency syndromes (PID).

Biotest, a Grifols Group company, forecasts approximately $1 billion in revenue from sales in the USA of Yimmugo during the next seven years, following recent Food and Drug Administration (FDA) approval to treat primary immunodeficiencies (PID).

Yimmugo is the first Biotest medicine to be commercialized in the USA from its new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe, where Yimmugo has been commercialized since late 2022.